Atopic Dermatitis

Question 1

What is the biological responsible for blocking the signaling to IL-4 and 13 by binding to the IL-4R alpha cytokine?

Answer 1

Dupilumab (dupixent)

Question 2

What biologics are responsible for blocking cytokines IL-13

Answer 2

Tralokizumab (Adbry) & Lebrikizumab (ebglyss)

Question 3

What biological is responsible for blocking the IL-31 receptor?

Answer 3

Nemolizumab (Cim 331)

Question 4

FDA approvals for Dupilumab (dupixent) include:

Answer 4

Atopic dermatitis and prurigo Nodularis

Question 5

Tralokizumab (Adbry) is FDA approved for:

Answer 5

Atopic Dermatitis

Question 6

lebrokizumab (Egblyss) will be approved for what condition in 2024?

Answer 6

Atopic dermatitis

Question 7

Nemolizumab (mitchga and cim 331) will be approved for what conditions?

Answer 7

Atopic dermatitis and prurigo nodularis

Question 8

What are the common side effects of dupilumab (dupixent)?

Answer 8

-Injection site reaction
Conjunctivitis
-Blepharilis
-Oral herpes
- Keratitis
-Eye pruritus
-Other herpes simplex virus infection
-dry eyes

Question 9

What are the common side effects of tralokinumab (Adbry)?

Answer 9

-Conjunctivitis
-Injection Site Reaction
-Upper Respiratory Tract Infections
-Eosinophilia

Question 10

What are the common side effects of lebrikizumab (ebglyss)?

Answer 10

-Conjunctivitis
-Injection Site Reaction
-Nasopharyngitis
-Headache
-Herpes Infections

Question 11

What are the common side effects of nemolizumab (Cim 331 and mitchga)?

Answer 11

-Peripheral edema
-Atopic dermatitis
-Asthma

Question 12

Tralokizumab brand name?

Answer 12

Adbry

Question 13

Lebrikizumab brand name?

Answer 13

Ebglyss

Question 14

Dupilumab brand name?

Answer 14

Dupixent

Question 15

What is a second line topical therapy for atopic dermatitis

Answer 15

Calcineurin inhibitors (pimecrolimus(Elidel) and tacrolimus (protopic)), PDE-4inhibitors (crisaborole (eucrisa)), jak 1-2 inhibitor ( ruxolitinib (opzelura))